Targeted therapy for lung cancer uses drugs designed to block specific molecular abnormalities that drive tumor growth, and it has reshaped treatment for a disease that historically offered few good options beyond chemotherapy. More than fifteen targeted agents have received FDA approval for at least seven distinct oncogenic drivers in non-small cell lung cancer (NSCLC) alone, turning what was once a grim prognosis into something more manageable for many patients.1PubMed Central. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future The catch is that these drugs only work when the tumor carries the right molecular alteration, which means getting tested is as important as getting treated.
How Doctors Decide Who Qualifies
Targeted therapy is not a one-size-fits-all treatment. It works by exploiting a tumor’s dependence on a specific mutated protein or gene rearrangement. If a tumor’s growth is fueled by, say, a mutation in the EGFR gene, then a drug that blocks that mutant protein can shrink the cancer far more effectively than traditional chemotherapy, and with fewer side effects. But if the tumor does not have that mutation, the drug is useless.
That means every patient with advanced NSCLC should undergo molecular profiling, typically through next-generation sequencing (NGS) of a tissue biopsy sample. The test screens for a panel of known actionable mutations all at once: EGFR, ALK, ROS1, BRAF V600E, RET, MET exon 14 skipping, NTRK fusions, KRAS G12C, HER2, and others.2PubMed Central. Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies When a tissue sample is unavailable or insufficient, a liquid biopsy, which analyzes fragments of tumor DNA circulating in the blood, can serve as an alternative. Liquid biopsy and tissue biopsy often agree on common mutations like EGFR, but discordance does occur. The blood test sometimes picks up mutations the tissue sample misses, and vice versa, because tumors shed DNA unevenly and biopsies only sample one spot in a heterogeneous mass.3Breathe. Liquid biopsy in lung cancer
In one prospective study, overall concordance between tissue and plasma sequencing for at least one shared genomic alteration was about 57%. However, when the blood test did detect an oncogenic driver, tissue testing confirmed it roughly 96% of the time, and the liquid biopsy directly led to matched targeted therapy in about one in five patients.4JNCI: Journal of the National Cancer Institute. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers The practical upshot for patients: if one test comes back negative or inconclusive, it can be worth pursuing the other.
EGFR Mutations and the Three Generations of Treatment
EGFR mutations are the most common actionable targets in NSCLC, particularly in adenocarcinomas and in patients who have never smoked. The first drugs developed against this target, erlotinib and gefitinib, were a genuine leap forward. They shrank tumors more reliably and with less toxicity than platinum-based chemotherapy.5PubMed Central. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy The problem was that nearly every tumor eventually found a way around the blockade. The most frequent escape route, accounting for over half of cases, was a secondary mutation called T790M that changed the shape of the EGFR protein just enough to prevent the drug from binding.6PubMed Central. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
That discovery prompted the development of third-generation drugs, of which osimertinib is the best known and the only one with regulatory approval in this class. Osimertinib was engineered to latch onto both the original sensitizing mutation and the T790M resistance mutation while largely ignoring the normal version of EGFR in healthy tissue, which reduces side effects like severe skin rash and diarrhea that earlier drugs caused. In trials comparing it head-to-head against chemotherapy in patients whose tumors had already developed T790M resistance, osimertinib proved clearly superior.7PubMed Central. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy It has since become the preferred first-line treatment for most EGFR-mutated advanced NSCLC, because giving the best drug upfront tends to delay resistance longer than saving it for later.
ALK Rearrangements and the Brain Metastasis Problem
ALK gene rearrangements occur in a smaller fraction of NSCLC patients, but the drugs developed against them have been among targeted therapy’s biggest success stories. The original ALK inhibitor, crizotinib, worked well in the body but poorly in the brain, a serious limitation since ALK-positive lung cancer has a high tendency to spread there. Newer-generation ALK inhibitors like alectinib and brigatinib penetrate the central nervous system more effectively, and a systematic review found that second-generation ALK inhibitors significantly improved survival and intracranial responses compared with crizotinib.8BMJ Open. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
The third-generation drug lorlatinib has pushed the boundaries further. In the phase III CROWN trial, lorlatinib produced an objective response in about three-quarters of previously untreated ALK-positive patients, compared with roughly 58% for crizotinib. Among patients who already had measurable brain metastases, the intracranial response rate was 82% for lorlatinib versus 23% for crizotinib, and 71% of the lorlatinib patients achieved complete disappearance of brain lesions.9PubMed. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer At one year, only 7% of patients who started on lorlatinib and had brain metastases at baseline experienced progression in the brain, compared with 72% in the crizotinib group.10PubMed Central. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study For patients with ALK-positive disease, brain metastases are no longer the near-automatic death sentence they once were.
KRAS G12C and the “Undruggable” Target
KRAS mutations are actually the most common oncogenic drivers in NSCLC, but for decades researchers could not figure out how to block them. The protein’s surface lacked the kind of pocket where a small-molecule drug could bind. KRAS earned a reputation in oncology as “undruggable.” That changed with the development of sotorasib and adagrasib, two drugs that exploit a previously unrecognized groove in the KRAS G12C variant of the protein.
Both drugs received accelerated FDA approval. Sotorasib showed an overall response rate of about 41% and kept disease from progressing for a median of roughly six months; in a confirmatory phase III trial it outperformed standard chemotherapy with docetaxel. Adagrasib posted similar numbers, with a response rate of about 43% and a median time before disease progressed of six and a half months.11PubMed. Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib Those numbers are modest compared with what EGFR and ALK inhibitors achieve, and resistance tends to develop quickly. Still, for a target that seemed permanently out of reach, having any effective drugs is a significant milestone. Adagrasib also showed activity against brain metastases: among patients with stable brain lesions, about a third had a confirmed intracranial response, and the median overall survival was around 12.6 months.12PubMed. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation
When Targeted Therapy Stops Working
Resistance is the central frustration of targeted therapy. Nearly every patient who responds to a targeted drug will eventually see the cancer find a workaround. The mechanisms fall into two broad categories. The first is on-target: the tumor develops new mutations in the gene the drug is designed to block, physically altering the drug’s binding site. The T790M mutation that defeated early EGFR drugs is the classic example. Even osimertinib, which was built to overcome T790M, faces its own resistance mutations. The resistance patterns differ depending on whether osimertinib is used as a first treatment or after earlier drugs have already failed, which reflects the tumor’s evolutionary history under different rounds of drug pressure.13PubMed Central. Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
The second category is off-target or “bypass” resistance, where the tumor activates an entirely different signaling pathway to keep growing, making the original drug irrelevant even though it is still blocking its intended target. MET gene amplification is one of the most important bypass mechanisms for EGFR-targeted drugs. It has long been recognized as a resistance route against first- and second-generation EGFR inhibitors and appears to be a key mechanism when tumors escape osimertinib as well, particularly when osimertinib is used upfront.14PubMed Central. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer This has fueled interest in combining EGFR and MET inhibitors together, a strategy now in advanced clinical testing. In rarer cases, tumors can undergo a wholesale transformation, changing from one type of lung cancer to another entirely, which makes the original targeted drug ineffective.
Side Effects Compared with Chemotherapy
Targeted therapies are generally easier to tolerate than traditional chemotherapy, but they are not side-effect-free. Each class of drug comes with its own characteristic toxicities. EGFR inhibitors commonly cause skin rash (often acne-like), diarrhea, and dry skin. ALK inhibitors like lorlatinib can cause weight gain, elevated cholesterol, and cognitive or mood changes. KRAS G12C inhibitors frequently cause gastrointestinal symptoms, liver enzyme elevations, and fatigue. In the adagrasib trial, almost all patients experienced some treatment-related adverse event, and about 45% had a grade 3 or higher event, though fewer than 7% stopped the drug because of side effects.15PubMed. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation
One side effect that crosses drug classes is drug-induced pneumonitis, an inflammation of the lung tissue. Although this is more commonly associated with immunotherapy, it also occurs with targeted agents including EGFR inhibitors. EGFR-inhibitor-associated lung inflammation can present as worsening shortness of breath and low oxygen levels, and in rare instances it can progress rapidly with high mortality.16PubMed. Pulmonary toxicity of systemic lung cancer therapy In most cases, stopping the drug and starting corticosteroids is enough, but more severe presentations require additional treatment.17PubMed Central. Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer Patients on any targeted therapy should report new or worsening breathing symptoms promptly.
Targeted Therapy After Surgery for Early-Stage Disease
For years, targeted therapy was reserved for patients with advanced or metastatic lung cancer. That changed with the ADAURA trial, which tested osimertinib as an after-surgery (adjuvant) treatment for patients with completely resected EGFR-mutated NSCLC. The results were striking. At two years, 90% of patients with stage II to IIIA disease who received osimertinib were alive and free of disease recurrence, compared with 44% on placebo.18PubMed. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
More importantly, longer follow-up confirmed that this translated into a genuine survival advantage, not just delayed recurrence. Five-year overall survival was 85% in the osimertinib group versus 73% in the placebo group among patients with stage II to IIIA disease.19PubMed. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC This established osimertinib as the first targeted therapy to show an overall survival benefit after surgery for lung cancer. One lingering question is whether every patient who has surgery needs adjuvant therapy, or whether some can safely skip it. Researchers are now exploring whether detecting minimal residual disease, tiny traces of tumor DNA in the blood after surgery, can identify the patients who truly need further treatment versus those whose surgery was curative on its own.20PubMed Central. Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol
Why Targeted Therapy and Immunotherapy Usually Do Not Mix
Immunotherapy with checkpoint inhibitors has transformed lung cancer treatment for patients without actionable driver mutations, but for patients whose tumors carry mutations like EGFR or ALK, immunotherapy tends to work poorly on its own. These tumors often have low mutation burden and a type of immune microenvironment that does not respond well to checkpoint blockade. The intuitive next step would be to combine the two approaches, but that has proven difficult. Combining EGFR inhibitors with PD-1 or PD-L1 inhibitors, for example, has produced unexpectedly high rates of serious toxicity, particularly liver inflammation and lung damage, in early trials.21Sage Journals / PubMed Central. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) The field has largely moved toward using these treatments sequentially rather than simultaneously, typically starting with targeted therapy and considering immunotherapy only after targeted options have been exhausted and the tumor’s biology has shifted.
Who Is Not Getting Tested
None of these drugs can help if a patient never learns they carry the mutation. Testing rates remain far below where they should be. In a large U.S. study of over 28,000 NSCLC patients, only about 39% received molecular diagnostic testing. Black patients were tested at even lower rates: roughly 28% versus 40% for White patients. After adjusting for other factors, Black patients had about 36% lower odds of being tested, and patients living in higher-poverty areas also had reduced likelihood of testing.22PubMed Central. Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake This disparity has been echoed in other analyses as well.23PubMed Central. Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review
The picture is not uniform across all healthcare settings, though. A study focused on Medicaid patients found no significant differences in biomarker testing rates by race, suggesting that when insurance coverage is comparable, the gap may narrow.24JTO Clinical and Research Reports. Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study The issue appears to be driven substantially by access barriers: where patients receive care, whether their hospital has sequencing capabilities, and whether their oncologist orders comprehensive testing. For any patient newly diagnosed with NSCLC, asking specifically about molecular testing is worth doing.
When Multiple Driver Mutations Appear Together
Most of the time, actionable driver mutations in lung cancer are mutually exclusive, meaning a tumor is powered by one primary driver. But in rare cases, a tumor harbors two or more simultaneously. A large retrospective study found that among patients with at least one actionable mutation, about 39% of those cases also had a concurrent second actionable alteration. EGFR was the most frequently involved gene in these combinations, and the most common pairing was EGFR with a ROS1 rearrangement. For these patients, targeted treatment was the preferred approach, but the median time before disease progressed was only about six months, which is on the shorter end for targeted therapy.25PubMed Central. Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis These compound cases remain a clinical challenge because blocking one driver may not be enough when the tumor has a backup already wired in.
The Cost of Staying on Treatment
Targeted therapy drugs are taken continuously for as long as they work, which can be years. That creates a financial burden that adds up relentlessly. One economic analysis estimated the annual median cost of targeted therapy in lung cancer at roughly $230,000. Over four years, that compounds to more than $900,000 per patient. Treating a thousand patients for four years in the U.S. would cost over $900 million.26Medical Research Archives. Reducing the Financial Toxicity of Prolonged Therapy in Advanced/Metastatic Lung Cancer, Saving Methodology Even with insurance, copays and out-of-pocket expenses can be devastating, and financial stress has been shown to affect treatment adherence. Some researchers have proposed stepping down doses or reducing prices in later years of therapy, arguing that the same clinical benefit could be maintained at lower cost once the initial response has been established. This remains an area of active debate.
Older Patients and Dose Adjustments
Targeted therapies are often better tolerated than chemotherapy, which makes them attractive for older adults or those with significant health problems. But “better tolerated” does not mean identical. Older patients metabolize drugs differently. A pharmacokinetic study of erlotinib, one of the first EGFR inhibitors, found that the drug cleared from the body more slowly with increasing age, meaning older patients were effectively getting higher exposure at the same standard dose. This translated into more toxicity. The researchers suggested that starting older, frailer patients at a lower dose and then adjusting based on drug levels could reduce the risk of overexposure while maintaining effectiveness.27PubMed. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients This kind of individualized dosing is not yet standard practice for most targeted drugs, but it reflects a growing recognition that one dose does not fit all ages.
New Drug Designs on the Horizon
The current generation of targeted therapies works by blocking a protein’s activity. The next wave may work by destroying the protein entirely. A technology called PROTACs, for proteolysis targeting chimeras, consists of molecules designed to latch onto a disease-causing protein and escort it to the cell’s natural recycling machinery for disposal. Early PROTACs have been developed against several lung cancer targets, and researchers believe this approach could overcome some forms of drug resistance that defeat traditional inhibitors, because eliminating the protein may be harder for a tumor to evolve around than simply blocking its function.28PubMed Central. PROTAC therapy as a new targeted therapy for lung cancer
Antibody-drug conjugates, or ADCs, represent another rapidly expanding approach. These are engineered antibodies that seek out a specific protein on the cancer cell surface, latch on, get pulled inside, and then release a toxic payload directly inside the cell. ADCs targeting HER2, TROP2, and c-MET have already gained regulatory approval for NSCLC, and newer designs targeting HER3, EGFR, and other surface proteins are showing encouraging results in early-phase trials.29Oxford Academic (The Oncologist). Antibody drugs conjugates in non–small cell lung cancer: current status and challenges ADCs blur the line between targeted therapy and chemotherapy: they use a targeted delivery mechanism but carry a chemotherapy-like warhead, offering a way to bring cytotoxic power to tumors that have exhausted other options.
Small Cell Lung Cancer and the Search for Targets
Most of this article has focused on non-small cell lung cancer because that is where targeted therapy has had its greatest impact. Small cell lung cancer (SCLC), which accounts for roughly 15% of lung cancers, is a fundamentally different disease at the molecular level. It rarely carries the kind of single-gene driver mutations that make NSCLC tumors vulnerable to kinase inhibitors. SCLC is driven more by the loss of tumor suppressor genes than by the gain of druggable oncogenes, which has made developing targeted treatments far harder.
One emerging target in SCLC is DLL3, a protein found on the surface of most small cell tumors but rarely on normal adult tissues. Researchers are pursuing it through antibody-drug conjugates, bispecific antibodies that redirect immune cells toward the tumor, and even CAR T-cell therapy engineered to recognize DLL3.30PubMed Central. Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy These approaches are still in clinical trials, but they represent the most promising targeted therapy effort for a cancer type that has been stubbornly resistant to treatment advances for decades.